Epigenome-derived drugs: recent advances and future perspectives.
This review highlights the current knowledge of epigenetic targets of anticancer therapy and outlines the current limitations of epigenetic approaches and the difficulties in defining preventive tools and strategies. Promising strategies towards achieving the goal of developing effective epigenetic treatments are discussed, including restoration or enhancement of sensitivity to other treatment modalities, and combinations with other agents and new therapeutic areas.
Vogiatzi
Paraskevi
P
Department of Molecular Biology, Medical Genetics Unit, University of Siena, Siena, Italy.
Aimola
Pierpaolo
P
Scarano
Maria Irene
MI
Claudio
Pier Paolo
PP
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D044127:Epigenesis, Genetic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics
D000970:Antineoplastic Agents